Portal de Periódicos da CAPES

Cancer and Risk of COVID-19 Through a General Community Survey

2020; AlphaMed Press; Volume: 26; Issue: 1 Linguagem: Inglês

10.1634/theoncologist.2020-0572

1549-490X

Karla A. Lee, Wenjie Ma, Daniel Sikavi, David A. Drew, Long H. Nguyen, Ruth C. E. Bowyer, M. Jorge Cardoso, Tove Fall, Maxim B. Freidin, Maria F. Gomez, Mark S. Graham, Chuan‐Guo Guo, Amit D. Joshi, Sohee Kwon, Chun‐Han Lo, Mary Ní Lochlainn, Cristina Menni, Benjamin Murray, Raaj S. Mehta, Mingyang Song, Carole H. Sudre, Véronique Bataille, Thomas Varsavsky, Alessia Visconti, Paul W. Franks, Jonathan Wolf, Claire J. Steves, Sébastien Ourselin, Tim D. Spector, Andrew T. Chan,

Global Cancer Incidence and Screening

Individuals with cancer may be at high risk for coronavirus disease 2019 (COVID-19) and adverse outcomes. However, evidence from large population-based studies examining whether cancer and cancer-related therapy exacerbates the risk of COVID-19 infection is still limited. Data were collected from the COVID Symptom Study smartphone application since March 29 through May 8, 2020. Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared with participants without cancer, those living with cancer had a 60% increased risk of a positive COVID-19 test. Among patients with cancer, current treatment with chemotherapy or immunotherapy was associated with a 2.2-fold increased risk of a positive test. The association between cancer and COVID-19 infection was stronger among participants >65 years and males. Future studies are needed to identify subgroups by tumor types and treatment regimens who are particularly at risk for COVID-19 infection and adverse outcomes.